TITLE

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

AUTHOR(S)
Martin, Daniel F.; Maguire, Maureen G.; Gui-shuang Ying; Grunwald, Juan E.; Fine, Stuart L.; Jaffe, Glenn J.
PUB. DATE
May 2011
SOURCE
New England Journal of Medicine;5/19/2011, Vol. 364 Issue 20, p1897
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data. Methods: In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation. The primary outcome was the mean change in visual acuity at 1 year, with a noninferiority limit of 5 letters on the eye chart. Results: Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab as needed was equivalent to monthly ranibizumab, although the comparison between bevacizumab as needed and monthly bevacizumab was inconclusive. The mean decrease in central retinal thickness was greater in the ranibizumab-monthly group (196 �m) than in the other groups (152 to 168 �m, P=0.03 by analysis of variance). Rates of death, myocardial infarction, and stroke were similar for patients receiving either bevacizumab or ranibizumab (P>0.20). The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66), with excess events broadly distributed in disease categories not identified in previous studies as areas of concern. Conclusions: At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. Differences in rates of serious adverse events require further study. (Funded by the National Eye Institute; ClinicalTrials.gov number, NCT00593450.) N Engl J Med 2011;364:1897-908.
ACCESSION #
60727962

 

Related Articles

  • Update: Phase II study outcomes encouraging for treating exudative AMD with combination therapy. Guttman, Cheryl // Ophthalmology Times;11/15/2008, Vol. 33 Issue 22, p18 

    The article cites key findings from an 18-month phase II clinical trial in the U.S. indicating that the combination of epiretinal brachytherapy and bevacizumab is an effective and safe way to treat exudative age-related macular degeneration (AMD). The combination therapy also minimizes the need...

  • A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Potter, M. J.; Claudio, C. C.; Szabo, S. M. // British Journal of Ophthalmology;Feb2010, Vol. 94 Issue 2, p174 

    Aim To determine if reduced light-dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over 6 months compared with bevacizumab monotherapy in neovascular age-related macular degeneration (AMD). Methods Thirty-six patients with...

  • Updates on the Clinical Trials in Diabetic Macular Edema. Demirel, Sibel; Argo, Colby; Agarwal, Aniruddha; Parriott, Jacob; Sepah, Yasir Jamal; Do, Diana V.; Quan Dong Nguyen // Middle East African Journal of Ophthalmology;Jan-Mar2016, Vol. 23 Issue 1, p3 

    In this era of evidence‑based medicine, significant progress has been made in the field of pharmacotherapeutics for the management of diabetic macular edema (DME). A number of landmark clinical trials have provided strong evidence of the safety and efficacy of agents such as...

  • Ranibizumab and Bevacizumab for AMD.  // New England Journal of Medicine;12/8/2011, Vol. 365 Issue 23, p2237 

    No full text rights to any articles when data is not provided by the publisher.

  • Retreatment with Anti-VEGF After Stabilization of AMD.  // Review of Ophthalmology;Oct2012, Vol. 19 Issue 10, p80 

    The article informs that retreatment with anti-vascular endothelial growth factor (VEGF) is required for patients with neo-vascular age-related macular degeneration after a year of the drug Bevacizumab administration.

  • Doctors in England want to use Avastin routinely for wet AMD.  // PharmacoEconomics & Outcomes News;Feb2015, Vol. 722 Issue 1, p2 

    The article reports on the request of physicians in England towards the off-label utilization of Avastin or bevacizumab for wet age-related macular degeneration (AMD) through its approval by the Department of Health, National Health Service (NHS) and the General Media Council.

  • New Drugs Improve Vision, Ease AMD Treatment Burden.  // Cleveland Clinic Men's Health Advisor;Apr2012, Vol. 14 Issue 4, p3 

    The article discusses several effective treatments for patients with age-related macular degeneration (AMD). AMD affects the macular, the center of the retina responsible for detailed vision, which causes blind spots in one's central vision. It highlights two type of AMD such as atrophic or dry...

  • Controlled trial compares bevacizumab with ranibizumab, finds no difference in efficacy.  // Optometry Times;Nov2009, Vol. 1 Issue 8, p16 

    The article discusses research on the therapeutic efficacy of bevacizumab and ranibizumab. It references a study published in the online issue of the "American Journal of Ophthalmology." The study compared the efficacy of bevacizumab and ranibizumab in treating age-related macular degeneration...

  • Treatment updates reported at retina specialist symposium.  // Primary Care Optometry News;Jan2009, Vol. 14 Issue 1, p1 

    The article reports on the claim of researcher Tom S. Chang that there is a difference in short-term biologic effect and durability of activity between anti-vascular endothelial growth factor bevacizumab and ranibizumab. Chang stated that this leads to differences in remission intervals in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics